08/12/2025 10:11
|
Medical, Health & Aged Care
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLL
Sonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in...